To gain mechanistic insights into the antileukemic activity of OST-01, we performed RNA-seq in primary CD34 + CD38- AML cells (n =  3) treated with OST-01 or vehicle (both at 1 μL/mL) for 24 h. This evidence concerns the gene CD38 and acute myeloid leukemia.